M D Prados

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Treatment of high-risk medulloblastoma and other primitive neuroectodermal tumors with reduced dose craniospinal radiation therapy and multi-agent nitrosourea-based chemotherapy
    M D Prados
    Department of Neurosurgery, University of California, San Francisco, USA
    Pediatr Neurosurg 25:174-81. 1996
  2. ncbi Chemotherapy of brain tumors
    M D Prados
    Department of Neurosurgery, University of California, San Francisco 94117, USA
    Semin Surg Oncol 14:88-95. 1998
  3. ncbi A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404
    M D Prados
    University of California San Francisco, 94143 0372, USA
    Int J Radiat Oncol Biol Phys 45:1109-15. 1999
  4. ncbi Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy
    M D Prados
    Department of Neurosurgery, University of California San Francisco, San Francisco, CA 94143 0372, USA
    J Clin Oncol 17:3389-95. 1999
  5. ncbi Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen
    M D Prados
    Department of Neurological Surgery, School of Medicine, University of California, San Francisco, USA
    J Neurooncol 32:235-41. 1997
  6. ncbi Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report
    S M Chang
    Department of Neurosurgery, University of California, San Francisco, USA
    J Clin Oncol 16:2188-94. 1998
  7. ncbi Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme
    M D Prados
    Department of Neurosurgery, University of California San Francisco, San Francisco, CA 94143 0372, USA
    Int J Radiat Oncol Biol Phys 49:71-7. 2001
  8. ncbi Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report
    S M Chang
    University of California Medical Center, San Francisco, USA
    J Clin Oncol 17:984-90. 1999
  9. ncbi EGFR overexpression and radiation response in glioblastoma multiforme
    F G Barker
    Department of Neurological Surgery, Neuro Oncology Service and Brain Tumor Research Center, University of California, San Francisco, California, USA
    Int J Radiat Oncol Biol Phys 51:410-8. 2001
  10. ncbi Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/- hyperthermia for glioblastoma multiforme
    P K Sneed
    Department of Radiation Oncology, University of California, San Francisco 94143 0226, USA
    Int J Radiat Oncol Biol Phys 40:287-95. 1998

Collaborators

Detail Information

Publications18

  1. ncbi Treatment of high-risk medulloblastoma and other primitive neuroectodermal tumors with reduced dose craniospinal radiation therapy and multi-agent nitrosourea-based chemotherapy
    M D Prados
    Department of Neurosurgery, University of California, San Francisco, USA
    Pediatr Neurosurg 25:174-81. 1996
    ....
  2. ncbi Chemotherapy of brain tumors
    M D Prados
    Department of Neurosurgery, University of California, San Francisco 94117, USA
    Semin Surg Oncol 14:88-95. 1998
    ..As part of a multimodality approach that includes surgery and radiotherapy, chemotherapy has a significant role to play in the treatment of both adults and children with brain neoplasms...
  3. ncbi A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404
    M D Prados
    University of California San Francisco, 94143 0372, USA
    Int J Radiat Oncol Biol Phys 45:1109-15. 1999
    ....
  4. ncbi Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy
    M D Prados
    Department of Neurosurgery, University of California San Francisco, San Francisco, CA 94143 0372, USA
    J Clin Oncol 17:3389-95. 1999
    ..To determine any differences in outcome for patients with anaplastic astrocytoma (AA) treated with adjuvant carmustine (BCNU) versus procarbazine, lomustine, and vincristine (PCV) chemotherapy...
  5. ncbi Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen
    M D Prados
    Department of Neurological Surgery, School of Medicine, University of California, San Francisco, USA
    J Neurooncol 32:235-41. 1997
    ..This regimen was safe, able to be delivered in the outpatient setting, and produced prolonged periods of disease stabilization in children with low-grade gliomas...
  6. ncbi Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report
    S M Chang
    Department of Neurosurgery, University of California, San Francisco, USA
    J Clin Oncol 16:2188-94. 1998
    ..To determine the maximum-tolerated dose (MTD) of paclitaxel administered as a 3-hour infusion in patients with recurrent malignant glioma...
  7. ncbi Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme
    M D Prados
    Department of Neurosurgery, University of California San Francisco, San Francisco, CA 94143 0372, USA
    Int J Radiat Oncol Biol Phys 49:71-7. 2001
    ....
  8. ncbi Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report
    S M Chang
    University of California Medical Center, San Francisco, USA
    J Clin Oncol 17:984-90. 1999
    ..To determine the response rate, time to treatment failure, and toxicity of phenylacetate in patients with recurrent malignant glioma and to identify plasma concentrations achieved during repeated continuous infusion of this agent...
  9. ncbi EGFR overexpression and radiation response in glioblastoma multiforme
    F G Barker
    Department of Neurological Surgery, Neuro Oncology Service and Brain Tumor Research Center, University of California, San Francisco, California, USA
    Int J Radiat Oncol Biol Phys 51:410-8. 2001
    ..We tested whether these abnormalities correlated with clinical heterogeneity in GM response to radiation treatment...
  10. ncbi Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/- hyperthermia for glioblastoma multiforme
    P K Sneed
    Department of Radiation Oncology, University of California, San Francisco 94143 0226, USA
    Int J Radiat Oncol Biol Phys 40:287-95. 1998
    ..To determine if adjuvant interstitial hyperthermia (HT) significantly improves survival of patients with glioblastoma undergoing brachytherapy boost after conventional radiotherapy...
  11. ncbi A Phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants: a North American Brain Tumor Consortium report
    S M Chang
    Department of Neurosurgery, University of California Medical Center, San Francisco, California, USA
    Cancer 91:417-22. 2001
    ..Secondary objectives were to determine the time period to treatment failure, to evaluate toxicities, and to obtain pharmacokinetic data...
  12. ncbi Phase I/II study of enzastaurin (ENZ) plus temozolomide (TMZ) and radiation therapy (XRT) in patients with glioblastoma multiforme (GBM) or gliosarcoma (GS)
    N A Butowski
    University of California San Francisco, San Francisco, CA Eli Lilly and Company, Indianapolis, IN
    J Clin Oncol 26:3559. 2008
    ..Secondary objectives included safety, PK and pharmacodynamic (PD) parameters, response, quality of life (QOL), and utility of MR spectroscopy and perfusion imaging...
  13. ncbi Late radiation injury following hyperfractionated craniospinal radiotherapy for primitive neuroectodermal tumor
    C Russo
    Brain Tumor Research Center of the Department of Neurological Surgery, School of Medicine, University of California, San Francisco, USA
    Int J Radiat Oncol Biol Phys 44:85-90. 1999
    ..To document the late radiographic change following hyperfractionated craniospinal radiotherapy for primitive neuroectodermal tumor...
  14. ncbi A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM)
    T F Cloughesy
    University of California, Los Angeles, CA Comprehensive Cancer Center, San Francisco, CA Henry Ford Health System, Detroit, MI Memorial Sloan Kettering Cancer Center, New York, NY University of Virginia, Charlottesville, VA University of Texas M D Anderson Cancer Center, Houston, TX Genentech, Inc, South San Francisco, CA Duke University, Durham, NC
    J Clin Oncol 26:2010b. 2008
    ..In a single-arm PhII trial of BV + CPT in recurrent GBM, activity was demonstrated, warranting further investigation of clinical benefit of BV alone, and in combination with CPT (Vredenburgh J, JCO 2007)...
  15. ncbi Age and radiation response in glioblastoma multiforme
    F G Barker
    Neuro Oncology Service, Brain Tumor Research Center, Department of Neurological Surgery, University of California, San Francisco, San Francisco, USA
    Neurosurgery 49:1288-97; discussion 1297-8. 2001
    ..Radiographically assessed tumor response to external beam radiation therapy is an important prognostic factor in GM. We hypothesized that older GM patients might have more radioresistant tumors...
  16. ncbi 15-year results for upfront TPDCV chemotherapy phase II trial for pediatric low-grade hypothalamic/chiasmatic gliomas
    K K Mishra
    University of California San Francisco, San Francisco, CA
    J Clin Oncol 26:10041. 2008
    ..Preliminary data has been presented previously (Prados et al, JCO 32:235-241, 1997; ASTRO 49th Annual Meeting, 2007)...
  17. ncbi Phase II trials of erlotinib or gefitinib in patients with recurrent meningiomas
    A D Norden
    Dana Farber Cancer Institute, Boston, MA Northwestern University, Chicago, IL University of California, San Francisco, San Francisco, CA Memorial Sloan Kettering Cancer Center, New York, NY University of Texas M D Anderson Cancer Center, Houston, TX University of California, Los Angeles, Los Angeles, CA University of Pittsburgh, Pittsburgh, PA
    J Clin Oncol 27:2062. 2009
    ..We have pooled the data and report the results here...
  18. ncbi Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery
    E E Graves
    Departments of Radiology, University of California, San Francisco 94143, USA
    AJNR Am J Neuroradiol 22:613-24. 2001
    ..Evaluation of metabolic changes with proton MR spectroscopy and structural changes with MR imaging improved tissue discrimination and provided correlation with histologic findings...